NTQ3617

NTQ3617 is an orally bioavailable small molecule inhibitor specifically targeting the KRAS G12C mutation, developed by Nanjing Chia Tai Tianqing Pharmaceutical. KRAS is a GTPase that functions as a molecular switch in signaling pathways like MAPK/ERK, which regulate cell proliferation and survival. The G12C mutation results in a constitutive activation of the protein, driving the growth of various malignancies, including non-small cell lung cancer and colorectal cancer. NTQ3617 works by covalently binding to the cysteine residue at position 12 in the inactive GDP-bound state of the KRAS protein, effectively locking it in an off conformation and blocking downstream oncogenic signaling. It is currently in early-stage clinical development for the treatment of advanced solid tumors harboring the KRAS G12C mutation.